MCLA-129 for advanced EGFR- and MET-positive lung and other cancers
Treatments studied
Part of Cancer, Digestive system, Lungs & breathing clinical trials.
This early-phase trial tests MCLA-129, an antibody that targets EGFR and MET, in people with advanced cancers that have specific lab “biomarker” results. It’s for patients whose cancer has grown after standard treatments or can’t take standard treatment, with the goal of shrinking tumors and improving symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older.
- Have advanced (metastatic or unresectable) NSCLC or another solid tumor, and the disease has grown after standard treatment or you can’t tolerate it (or you refuse standard treatment in Part 1’s situation).
- Have the required tumor biomarker results from recent testing, depending on which study group (EGFR and/or MET positive, such as EGFR exon 20 insertion or MET exon 14 skipping, etc.).
- Be well enough to take treatment: ECOG 0–1 and expected survival of at least 3 months.
- Be able to follow study procedures, have informed consent, and have adequate blood and organ function (including no blood transfusions or growth factor support close to the first dose).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug that helps your immune system find and attack cancer cells that have a specific marker (MAGE-A1). It's for people with advanced solid tumors who have run out of standard options.
This study tests a new drug, MCLA-129, for people with advanced non-small cell lung cancer that has specific gene changes (EGFR and MET) and has stopped responding to standard treatments. The drug targets these changes to possibly slow or shrink the cancer.
This trial tests a new experimental drug called MCLA-158 (petosemtamab) for people with advanced solid tumors, especially head and neck cancer or colorectal cancer, that have not responded to standard treatments. The study aims to see if this drug can shrink tumors or slow their growth.
This study tests a new radioactive treatment for people with advanced solid tumors, such as certain lung, colon, head and neck, or bile duct cancers, that have stopped responding to standard treatments. The treatment targets a protein called c-MET found on cancer cells, aiming to deliver radiation directly to the tumor.
This trial tests a new two-drug combination (MCLA-129 and ensartinib) for people with advanced solid tumors that have a specific genetic change called MET amplification or overexpression. The goal is to see if this combo can shrink tumors or stop them from growing when other treatments have stopped working.
This trial tests a new drug called LM-168, either alone or combined with another cancer treatment, for people with advanced solid tumors that have not responded to standard therapies. The goal is to see if it can shrink tumors or slow their growth.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.